Wiki source
mTOR Inhibition and Rapamycin
A read-only view of this entry as wiki markup. This atlas is curated, so editing is disabled — but the source shows exactly how the page is structured.
# mTOR Inhibition and Rapamycin Portal: Longevity Science Stage: Preclinical robust, human trials early Evidence: Early human Template: Intervention Risk: Moderate Reversibility: Reversible Last reviewed: Jun 2026 == Summary == Rapamycin extends lifespan in multiple animal models by inhibiting mTOR, making it the most reproducible pharmacological longevity signal — and a live question for human healthspan trials. == Key takeaways == * Rapamycin is the most consistently lifespan-extending drug across model organisms, including mice started late in life. * The mechanism runs through mTOR, a central controller of growth, metabolism, and autophagy. * Human evidence targets immune function and specific conditions; broad healthspan benefit is unproven. == Mechanism == mTOR integrates signals about nutrients, energy, and growth factors. Sustained mTOR activity favors growth and protein synthesis; inhibiting it shifts cells toward maintenance, autophagy, and stress resistance — states associated with longer life in model organisms. Rapamycin and related rapalogs inhibit mTOR complex 1 strongly and complex 2 with chronic dosing. The dosing schedule matters: intermittent regimens aim to capture benefits while limiting immune suppression and metabolic side effects. == Human translation == The strongest human signal so far is immune: low-dose mTOR inhibition improved vaccine response in older adults in trials of rapalogs. Interest has since widened to healthspan endpoints, and investigator-led trials have tested tolerability and biomarkers in generally healthy older people. The open problem is endpoints. Aging is not an approved indication, side effects are real, and demonstrating benefit requires long, expensive trials with functional outcomes rather than biomarker shifts alone. == Open questions == * Which intermittent dosing schedules separate benefit from immune suppression? * Do biomarker changes in humans predict functional healthspan gains? == Watchlist == * Intermittent dosing trials * Immune aging endpoints * Rapalog selectivity == References == * NIA Interventions Testing Program — rapamycin — National Institute on Aging. https://www.nia.nih.gov/research/dab/interventions-testing-program-itp. Program that reproducibly extended mouse lifespan with rapamycin. * mTOR inhibition and immune function in aging — Mannick et al., Science Translational Medicine, 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/. Randomized trial showing improved vaccine response in older adults. == Categories == [[Category:Longevity Science]] [[Category:geroprotectors]] [[Category:mTOR]] [[Category:nutrient sensing]]